Literature DB >> 29178821

Mosaicism in Cutaneous Disorders.

Young H Lim1,2, Zoe Moscato1, Keith A Choate1,2.   

Abstract

Genetic mosaicism arises when a zygote harbors two or more distinct genotypes, typically due to de novo, somatic mutation during embryogenesis. The clinical manifestations largely depend on the differentiation status of the mutated cell; earlier mutations target pluripotent cells and generate more widespread disease affecting multiple organ systems. If gonadal tissue is spared-as in somatic genomic mosaicism-the mutation and its effects are limited to the proband, whereas mosaicism also affecting the gametes, such as germline or gonosomal mosaicism, is transmissible. Mosaicism is easily appreciated in cutaneous disorders, as phenotypically distinct mutant cells often give rise to lesions in patterns determined by the affected cell type. Genetic investigation of cutaneous mosaic disorders has identified pathways central to disease pathogenesis, revealing novel therapeutic targets. In this review, we discuss examples of cutaneous mosaicism, approaches to gene discovery in these disorders, and insights into molecular pathobiology that have potential for clinical translation.

Entities:  

Keywords:  RASopathy; epigenetic mosaicism; lines of Blaschko; nonsegmental mosaicism; revertant mosaicism; segmental mosaicism; somatic mutation

Mesh:

Substances:

Year:  2017        PMID: 29178821      PMCID: PMC8026264          DOI: 10.1146/annurev-genet-121415-121955

Source DB:  PubMed          Journal:  Annu Rev Genet        ISSN: 0066-4197            Impact factor:   16.830


  140 in total

1.  Identification of functioning sweat pores and visualization of skin temperature patterns in X-linked hypohidrotic ectodermal dysplasia by whole body thermography.

Authors:  R P Clark; M R Goff; K D MacDermot
Journal:  Hum Genet       Date:  1990-11       Impact factor: 4.132

2.  Activating HRAS mutation in nevus spilus.

Authors:  Kavita Y Sarin; Jennifer M McNiff; Shirley Kwok; Jinah Kim; Paul A Khavari
Journal:  J Invest Dermatol       Date:  2014-01-03       Impact factor: 8.551

3.  Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ.

Authors:  Matthew D Shirley; Hao Tang; Carol J Gallione; Joseph D Baugher; Laurence P Frelin; Bernard Cohen; Paula E North; Douglas A Marchuk; Anne M Comi; Jonathan Pevsner
Journal:  N Engl J Med       Date:  2013-05-08       Impact factor: 91.245

Review 4.  RAS oncogenes: weaving a tumorigenic web.

Authors:  Yuliya Pylayeva-Gupta; Elda Grabocka; Dafna Bar-Sagi
Journal:  Nat Rev Cancer       Date:  2011-10-13       Impact factor: 60.716

5.  Germline KRAS mutations cause Noonan syndrome.

Authors:  Suzanne Schubbert; Martin Zenker; Sara L Rowe; Silke Böll; Cornelia Klein; Gideon Bollag; Ineke van der Burgt; Luciana Musante; Vera Kalscheuer; Lars-Erik Wehner; Hoa Nguyen; Brian West; Kam Y J Zhang; Erik Sistermans; Anita Rauch; Charlotte M Niemeyer; Kevin Shannon; Christian P Kratz
Journal:  Nat Genet       Date:  2006-02-12       Impact factor: 38.330

6.  NRAS Mutations in Noonan Syndrome.

Authors:  E Denayer; H Peeters; L Sevenants; M Derbent; J P Fryns; E Legius
Journal:  Mol Syndromol       Date:  2012-05-03

7.  MicroRNA and Epigenetics: Diagnostic and Therapeutic Opportunities.

Authors:  Paloma Del C Monroig; George A Calin
Journal:  Curr Pathobiol Rep       Date:  2013-03

8.  Segmental neurofibromatosis type 2: discriminating two hit from four hit in a patient presenting multiple schwannomas confined to one limb.

Authors:  Elisabeth Castellanos; Isabel Bielsa; Cristina Carrato; Imma Rosas; Ares Solanes; Cristina Hostalot; Emilio Amilibia; José Prades; Francesc Roca-Ribas; Conxi Lázaro; Ignacio Blanco; Eduard Serra
Journal:  BMC Med Genomics       Date:  2015-01-24       Impact factor: 3.063

9.  Whole-exome sequencing reveals somatic mutations in HRAS and KRAS, which cause nevus sebaceus.

Authors:  Jonathan L Levinsohn; Li C Tian; Lynn M Boyden; Jennifer M McNiff; Deepak Narayan; Erin S Loring; Duri Yun; Jeffrey L Sugarman; John D Overton; Shrikant M Mane; Richard P Lifton; Amy S Paller; Annette M Wagner; Richard J Antaya; Keith A Choate
Journal:  J Invest Dermatol       Date:  2012-10-25       Impact factor: 8.551

10.  Ultra-sensitive droplet digital PCR for detecting a low-prevalence somatic GNAQ mutation in Sturge-Weber syndrome.

Authors:  Yuri Uchiyama; Mitsuko Nakashima; Satoshi Watanabe; Masakazu Miyajima; Masataka Taguri; Satoko Miyatake; Noriko Miyake; Hirotomo Saitsu; Hiroyuki Mishima; Akira Kinoshita; Hajime Arai; Ko-ichiro Yoshiura; Naomichi Matsumoto
Journal:  Sci Rep       Date:  2016-03-09       Impact factor: 4.379

View more
  5 in total

1.  Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa.

Authors:  K Twaroski; C Eide; M J Riddle; L Xia; C J Lees; W Chen; W Mathews; D R Keene; J A McGrath; J Tolar
Journal:  Br J Dermatol       Date:  2019-07-08       Impact factor: 9.302

2.  Novel hereditary spherocytosis-associated splice site mutation in the ANK1 gene caused by parental gonosomal mosaicism.

Authors:  Xiong Wang; Na Shen; Ming Huang; Yanjun Lu; Qun Hu
Journal:  Haematologica       Date:  2018-02-15       Impact factor: 9.941

3.  A postzygotic KRAS mutation in a patient with Schimmelpenning syndrome presenting with lipomatosis, renovascular hypertension, and diabetes mellitus.

Authors:  Misako Nagatsuma; Kei Takasawa; Takeru Yamauchi; Ryuichi Nakagawa; Tomoko Mizuno; Eriko Tanaka; Kouhei Yamamoto; Noriko Uemura; Kenichi Kashimada; Tomohiro Morio
Journal:  J Hum Genet       Date:  2018-11-16       Impact factor: 3.172

4.  Mutations in KRT10 in epidermolytic acanthoma.

Authors:  Shayan Cheraghlou; Lihi Atzmony; Simon F Roy; Jennifer M McNiff; Keith A Choate
Journal:  J Cutan Pathol       Date:  2020-02-19       Impact factor: 1.587

5.  Cell non-autonomy amplifies disruption of neurulation by mosaic Vangl2 deletion in mice.

Authors:  Gabriel L Galea; Eirini Maniou; Timothy J Edwards; Abigail R Marshall; Ioakeim Ampartzidis; Nicholas D E Greene; Andrew J Copp
Journal:  Nat Commun       Date:  2021-02-19       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.